Skip to main content
Premium Trial:

Request an Annual Quote

Lloyd Sanders

Epic Sciences has appointed Lloyd Sanders as president and CEO. He will be replacing Murali Prahalad, who is stepping down and has been appointed to the board of directors. Sanders joins the firm with 20 years of diagnostic and pharmaceutical industry experience. He previously served as president of Myriad Genetics' oncology segment. Prior to Myriad, Sanders served as chief operating officer at Dey Pharma. Before Dey Pharma, Sanders worked at Genta, where he acted as VP of marketing and later COO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.